[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Der Nervenarzt
K KolleweS Petri

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to death after 3 to 5 years. The glutamate antagonist Riluzole currently is the only drug with marginal therapeutic benefit, but its effect on survival is modest, with an average increase of only 3-4 months. Therefore symptomatic treatment still is the most important. Further neuroprotective agents are currently under investigation, both in transgenic animal models of ALS and clinical trials in ALS patients. This review summarizes the current state of clinical studies in ALS patients in the context of underlying therapeutic mechanisms.

References

Jul 1, 1995·Annals of Neurology·J D RothsteinR W Kuncl
Mar 3, 1994·The New England Journal of Medicine·G BensimonV Meininger
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·T Q DoC F Clarke
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·R T MatthewsM F Beal
Aug 27, 1999·Trends in Pharmacological Sciences·M Patel, B J Day
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B J GuglielmoR A Jacobs
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·P PasinelliD W Cleveland
Jun 2, 2001·The New England Journal of Medicine·L P Rowland, N A Shneider
Jun 13, 2002·Neuroreport·Ludo Van Den BoschWim Robberecht
Aug 8, 2002·Neuron·Tony Wyss-Coray, Lennart Mucke
Sep 25, 2002·Neurobiology of Disease·Jasna KrizJean-Pierre Julien
Jan 31, 2003·Annals of Neurology·Wenhua ZhangRobert M Friedlander
Apr 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·D N AngelovM Schwartz
Aug 2, 2003·Biochemical and Biophysical Research Communications·Judit HargitaiDavid S Latchman
Sep 18, 2003·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Michael Strong, Jeffrey Rosenfeld
Jan 22, 2004·Neuromuscular Disorders : NMD·Eugenio MercuriChristina Brahe

❮ Previous
Next ❯

Citations

Jun 16, 2012·Science·Tjisse van der HeideJan A van Gils
Feb 24, 2009·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Andrew Eisen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Related Papers

Expert Opinion on Investigational Drugs
Jaydeep M Bhatt, Paul H Gordon
Journal of the Neurological Sciences
N Le ForestierVincent Meininger
© 2021 Meta ULC. All rights reserved